SunWay Biotech Co

SunWay Biotech Co Net Debt

The Net Debt of SunWay Biotech Co (1271.TWO) as of Nov 22, 2026 is 408.86 M TWD. In the previous year, Net Debt was -43.85 M TWD — a change of -1,032.35% (higher).

Net Debt

408.86 MTWD

YoY

-1,032.35%

Last updated:

Net Debt of SunWay Biotech Co is 2025 408.86 M TWD. Net Debt of SunWay Biotech Co was 2024 -43.85 M TWD. It decreases by -1,032.35% higher compared to the previous year.

The SunWay Biotech Co Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2019
-45.67 M TWD
Jan 1, 2020
-278.39 M TWD
Jan 1, 2021
-325.76 M TWD
Jan 1, 2022
-52.23 M TWD
Jan 1, 2023
-58.64 M TWD
Jan 1, 2024
-43.85 M TWD
Jan 1, 2025
408.86 M TWD
The SunWay Biotech Co Net Debt history
YEARNet DebtYoY
408.86 MTWD-1,032.35%
-43.85 MTWD-25.22%
-58.64 MTWD+12.28%
-52.23 MTWD-83.97%
-325.76 MTWD+17.01%
-278.39 MTWD+509.64%
-45.67 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co., Ltd. generates revenue through the research, development, manufacture, and sale of red yeast health food products. The company's main products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which target digestive health, bacterial ecology regulation, immunity, and allergy management. These products are sold in both domestic and overseas markets, catering to consumers seeking natural health solutions. The firm focuses on health food segments where digestive and immune support are key consumer needs. The company's product portfolio emphasizes specific strains like Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their functional benefits in digestion and immune regulation. These health foods are distributed across domestic and international channels, targeting health-conscious consumers who prioritize natural remedies. SunWay Biotech leverages its research-driven approach to position these products in the health food market. SunWay Biotech Co., Ltd. operates within the health food industry, focusing on products that address digestive and immune health through natural ingredients. Its offerings are designed to improve bacterial ecology in the digestive tract and regulate immunity and allergies, appealing to a segment of consumers interested in preventive health solutions. The company's domestic and overseas market strategy ensures broad reach for its specialized health food products. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SunWay Biotech Co stock

Net Debt of SunWay Biotech Co is 408.86 M TWD in 2025.

Net Debt of SunWay Biotech Co changed from -43.85 M TWD to 408.86 M TWD, representing a -1,032.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's SunWay Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SunWay Biotech Co

All Key Metrics — SunWay Biotech Co